|
309 Companies |
|
473 Products |
|
473 Products |
|
224 Mechanisms of Action |
|
25 Trials |
|
4900 News |
|
| «12...87888990919293949596979899 |
- ||||| Hepatoren (ifetroban) / Cumberland
New P2 trial: Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients (clinicaltrials.gov) - Aug 30, 2011
P2, N=64, Recruiting, Sponsor: Cumberland Pharmaceuticals
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Clinical: Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=20, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
- ||||| INX 189 / BMS, Daklinza (daclatasvir) / BMS
New P2 trial: Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin (clinicaltrials.gov) - Aug 28, 2011
P2, N=210, Completed, Sponsor: Bristol-Myers Squibb
- Clinical: Autoregulation Assessment During Liver Transplantation (clinicaltrials.gov) - Aug 25, 2011
P=N/A, N=20, Not yet recruiting, Sponsor: Johns Hopkins University
- ||||||| ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial completion: Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) (clinicaltrials.gov) - Aug 25, 2011
P3, N=102, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed
- | GSK 2336805 / J&J
New P1 trial: Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 (clinicaltrials.gov) - Aug 25, 2011
P1, N=20, Completed, Sponsor: GlaxoSmithKline
- gemcitabine / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Aug 25, 2011
P2, N=45, Completed, Sponsor: Mahidol University
Active, not recruiting --> Completed Recruiting --> Completed
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
New P1 trial: Bioequivalence of LB80380 Free Base and Maleate Salt Tablets (clinicaltrials.gov) - Aug 24, 2011
P1, N=32, Completed, Sponsor: LG Life Sciences
- colestipol / Generic mfg.
New P2/3 trial: Sorbent Therapy of the Cutaneous Porphyrias (clinicaltrials.gov) - Aug 23, 2011
P2/3, N=4, Completed, Sponsor: Brigham and Women's Hospital
- |||| Fendrix (hepatitis B (rDNA) vaccine adjuvanted, adsorbed) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion, Combination therapy, IO biomarker: Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine (clinicaltrials.gov) - Aug 18, 2011
P2, N=713, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- rosiglitazone / Generic mfg.
Trial termination: Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (clinicaltrials.gov) - Aug 17, 2011
P4, N=26, Terminated, Sponsor: Seoul St. Mary's Hospital
Active, not recruiting --> Completed Suspended --> Terminated; because of withdrawal of Avandia sale due to its risks outweigh its benefits
- rosiglitazone / Generic mfg.
Enrollment change: Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (clinicaltrials.gov) - Aug 17, 2011
P4, N=26, Terminated, Sponsor: Seoul St. Mary's Hospital
Suspended --> Terminated; because of withdrawal of Avandia sale due to its risks outweigh its benefits N=40 --> 26
- | namodenoson (CF102) - Can / Fite
Trial completion, P1/2 data: A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Aug 17, 2011
P1/2, N=32, Completed, Sponsor: Can-Fite BioPharma
N=40 --> 26 Recruiting --> Completed
- | Nabi-HB (hepatitis B immune globulin) / ADMA Biologics
New P1/2 trial, Combination therapy: Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation (clinicaltrials.gov) - Aug 17, 2011
P1/2, N=30, Completed, Sponsor: Biotest Pharmaceuticals Corporation
- | Hetlioz (tasimelteon) / Vanda
Trial completion: Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment (clinicaltrials.gov) - Aug 17, 2011
P1, N=29, Completed, Sponsor: Vanda Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Prediction of Hepatitis C Recurrence in Liver Transplant Recipients (clinicaltrials.gov) - Aug 16, 2011
P=N/A, N=24, Terminated, Sponsor: Northwestern University
Active, not recruiting --> Completed Recruiting --> Terminated; This project is no longer being adequately supported to allow completion
- Enrollment change: Prediction of Hepatitis C Recurrence in Liver Transplant Recipients (clinicaltrials.gov) - Aug 16, 2011
P=N/A, N=24, Terminated, Sponsor: Northwestern University
Recruiting --> Terminated; This project is no longer being adequately supported to allow completion N=100 --> 24
- || New P2/3 trial: InVITED: Increasing Viral Testing in the Emergency Department (clinicaltrials.gov) - Aug 16, 2011
P2/3, N=398, Completed, Sponsor: Rhode Island Hospital
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion: Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis (clinicaltrials.gov) - Aug 16, 2011
P4, N=29, Completed, Sponsor: Department of Veterans Affairs
N=100 --> 24 Active, not recruiting --> Completed
- combretastatin A1 di-phosphate (OXi4503) / Oncotelic
Enrollment change, Monotherapy: Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (clinicaltrials.gov) - Aug 16, 2011
P1, N=16, Completed, Sponsor: OXiGENE
Active, not recruiting --> Completed N=63 --> 16
- favipiravir / Generic mfg.
New P1 trial: Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment (clinicaltrials.gov) - Aug 16, 2011
P1, N=36, Completed, Sponsor: FujiFilm Pharmaceuticals U.S.A., Inc.
- | combretastatin A1 di-phosphate (OXi4503) / Oncotelic
Trial completion, Monotherapy: Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden (clinicaltrials.gov) - Aug 16, 2011
P1, N=16, Completed, Sponsor: OXiGENE
N=63 --> 16 Active, not recruiting --> Completed
- New P1/2 trial: Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist (clinicaltrials.gov) - Aug 15, 2011
P1/2, N=45, Completed, Sponsor: University Medicine Greifswald
- Pegasys (pegylated interferon ? -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche, Xenical (orlistat) / Roche, GSK
Trial completion: Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus (clinicaltrials.gov) - Aug 15, 2011
P4, N=30, Completed, Sponsor: Brooke Army Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Aug 14, 2011
P4, N=220, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
- | pravastatin / Generic mfg., sorafenib / Generic mfg.
New P2 trial, Metastases: Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma (clinicaltrials.gov) - Aug 14, 2011
P2, N=216, Recruiting, Sponsor: Hospital Donostia
- | MB07133 / Xi'an XinTong Pharma
Enrollment change: Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 10, 2011
P1/2, N=28, Completed, Sponsor: Ligand Pharmaceuticals
Active, not recruiting --> Completed N=36 --> 28
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P4 trial: Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism (clinicaltrials.gov) - Aug 9, 2011
P4, N=240, Terminated, Sponsor: University of Vermont
- New P4 trial: The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients (clinicaltrials.gov) - Aug 8, 2011
P4, N=30, Recruiting, Sponsor: Seoul National University Hospital
- Flumadine (rimantadine) / AbbVie
New P2 trial, Combination therapy: HepRiACT: Hepatitis C Rimantadine and Antiviral Combination Therapy (clinicaltrials.gov) - Aug 8, 2011
P2, N=22, Recruiting, Sponsor: The Leeds Teaching Hospitals NHS Trust
- Trial termination: Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=26, Terminated, Sponsor: Mount Sinai School of Medicine
N=36 --> 28 Recruiting --> Terminated; low enrollment
- Enrollment change: Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=26, Terminated, Sponsor: Mount Sinai School of Medicine
Recruiting --> Terminated; low enrollment N=60 --> 26
- Clinical: Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=259, Completed, Sponsor: Govind Ballabh Pant Hospital
- ||||||| Trial completion: The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines (clinicaltrials.gov) - Aug 7, 2011
P2/3, N=1091, Completed, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
N=60 --> 26 Active, not recruiting --> Completed
- ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial completion, Observational data: Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=2, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Pegasys (pegylated interferon ? -2a) / Roche
Trial termination, Combination therapy: Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (clinicaltrials.gov) - Aug 7, 2011
P0, N=30, Terminated, Sponsor: University of Nebraska
Active, not recruiting --> Completed Not yet recruiting --> Terminated; new medications with improved response released